23rd International Congress of Parkinson’s Disease and Movement Disorders, Nice, France, September 22-26, 2019 – Impact of ND0612 on patient reported outcomes: A blinded rater study of 2 dosing regimens
23rd International Congress of Parkinson’s Disease and Movement Disorders, Nice, France, September 22-26, 2019 – BouNDless: An active-controlled randomized, double-blind double-dummy study of continuous ND0612 infusion in patients with fluctuating Parkinson’s disease
5th Congress of the European Academy of Neurology (EAN), June 29-July 2 2019, Oslo – The BeyoND study: Design and baseline characteristics of an international, multicenter study evaluating the long-term safety of ND0612 for Parkinson’s disease
5th World Parkinson Congress. Kyoto, Japan 4-7 June 2019 – Pharmacokinetics of ND0612 administered at different infusion sites and with different cannula lengths: An open-label, randomized, cross-over study in healthy volunteers
5th World Parkinson Congress. Kyoto, Japan 4-7 June 2019 – BouNDless: An active-controlled randomized, double-blind double-dummy study of continuous ND0612 infusion in patients with fluctuating Parkinson’s disease
American Academy of Neurology (AAN) 2019 Annual Meeting, Philadelphia May 4-11, 2019 – Efficacy of ND0612 for nocturnal problems and early morning OFF: A blinded rater study of 2 dosing regimens
AAN 2018, LA Oral presentation Efficacy and safety of subcutaneous L-dopa/carbidopa (ND0612H) infusion in fluctuating PD patients
EAN 2018, Lisbon e-poster presentation Pharmacokinetic and safety characterization of levodopa/carbidopa subcutaneous infusion (ND0612): Phase I studies in healthy volunteers and patients with fluctuating Parkinson’s disease
PAS-MDS 2018, Miami Poster A multicenter, parallel-group, rater-blinded, randomized clinical study investigating the efficacy, safety and tolerability of 2 dosing regimens of ND0612
MDS 2018, Hong Kong Poster The BeyoND study: Design and baseline characteristics of a study evaluating the long-term safety of ND0612 for motor fluctuations in Parkinson’s disease
MDS 2018, Hong Kong Poster Efficacy of ND0612 for nocturnal problems and early morning OFF
Poster presented at the MDS Vancouver 2017, ND0612 005b.
Poster presented at the MDS Vancouver 2017, ND0612 optimal carbidopa concentration.
Poster presented at the MDS Vancouver 2017, patient use perspective.
Poster presented at the MDS Vancouver 2017, ND0612 003 & 004.
Poster presented at the MDS Vancouver 2017, ND0612 006 Baseline characteristics.
Poster presented at the MDS Vancouver 2017, ND0612 006 results .
Poster presented at the AAN Boston2017 ND0701.
Poster presented at the World Parkinsons Congress Oregon 2016 ND0612_004.
Poster presented at the World Parkinsons Congress Oregon 2016 ND0701.
Poster presented at the World Parkinsons Congress Oregon 2016 ND0612 003.
Poster presented at the World Parkinsons Congress Oregon 2016 ND0612 006.
Poster presented at the World Parkinsons Congress Oregon 2016 Patient Use Prospective.
Poster presented at the 67th American Academy of Neurology Annual Meeting, April 2015, Washington, DC.
